Cefotaxime and Lamotrigine drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Cefotaxime (cefotaxime sodium) and Lamotrigine (lamotrigine). Common drug interactions include convulsion among females and brain oedema among males.

The phase IV clinical study analyzes what interactions people have when they take Cefotaxime and Lamotrigine. It is created by eHealthMe based on reports of 53 people who take the same drugs from the FDA, and is updated regularly.

What is Cefotaxime?

Cefotaxime has active ingredients of cefotaxime sodium. eHealthMe is studying from 7,559 Cefotaxime users. Check the latest studies of Cefotaxime.

What is Lamotrigine?

Lamotrigine has active ingredients of lamotrigine. It is often used in bipolar disorder. eHealthMe is studying from 76,638 Lamotrigine users. Check the latest studies of Lamotrigine.



On Jul, 21, 2026

53 people who take Cefotaxime and Lamotrigine together, and have interactions are studied.

Cefotaxime and Lamotrigine drug interactions.

What are the common drug interactions of Cefotaxime and Lamotrigine, by gender? *:

female:

  1. Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body)
  2. Blood glucose increased
  3. Cardiac arrest
  4. Ketoacidosis (high concentrations of ketone bodies in blood)
  5. Shock (a life-threatening condition with symptoms like low blood pressure, weakness, shallow breathing, cold, clammy skin)
  6. Drug rash with eosinophilia and systemic symptoms (adverse drug reactions with rash)
  7. Hepatic encephalopathy (spectrum of neuropsychiatric abnormalities in patients with liver failure)
  8. Hepatitis fulminant (life-threatening condition defined by significantly impaired liver function)
  9. Meningitis aseptic (a condition that causes the membranes covering your brain and spinal cord to become inflamed)
  10. Anaphylactic reaction (serious allergic reaction)

male:

  1. Brain oedema (excess accumulation of fluid in the intracellular or extracellular spaces of the brain)
  2. Aphasia (damage to the parts of the brain that control language)
  3. Developmental delay
  4. Encephalopathy (functioning of the brain is affected by some agent or condition)
  5. Ischaemia (insufficient supply of blood to an organ, usually due to a blocked artery)
  6. Pyrexia (fever)
  7. Hypoxic-ischaemic encephalopathy (a condition that occurs when the entire brain is deprived of an adequate oxygen supply, but the deprivation isn't total)
  8. Hypoxia (low oxygen in tissues)
  9. Mycoplasma infection (bacterial infection)
  10. Learning disability (difficulty in learning)

What are the common drug interactions of Cefotaxime and Lamotrigine, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

  1. Brain oedema (excess accumulation of fluid in the intracellular or extracellular spaces of the brain)
  2. Status epilepticus (a life-threatening condition in which the brain is in a state of persistent seizure)
  3. Aphasia (damage to the parts of the brain that control language)
  4. Dystonia (abnormal muscle tone)
  5. Cognitive disorder (mental health disorders affects learning, memory, perception, and problem solving)
  6. Hypotonia (low muscle tone)
  7. Learning disorder (the brain's disability to receive, process, store, respond to and communicate information)
  8. Movement disorder (neurological syndromes where they may be excess of movement or a paucity of movement that is not connected to weakness)
  9. Akinesia (loss of control of voluntary muscle movements)
  10. Cerebral atrophy (decrement in size of brain)

10-19:

  1. Akinesia (loss of control of voluntary muscle movements)
  2. Aphasia (damage to the parts of the brain that control language)
  3. Brain hypoxia (reduced supply of oxygen to the brain)
  4. Brain oedema (excess accumulation of fluid in the intracellular or extracellular spaces of the brain)
  5. Cerebral atrophy (decrement in size of brain)
  6. Cerebral ischaemia (insufficient blood flow to the brain to meet metabolic demand)
  7. Cognitive disorder (mental health disorders affects learning, memory, perception, and problem solving)
  8. Distributive shock (hock caused by poor distribution of the blood flow)
  9. Dystonia (abnormal muscle tone)
  10. Encephalopathy (functioning of the brain is affected by some agent or condition)

20-29:

n/a

30-39:

  1. Interstitial lung disease

40-49:

  1. Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body)
  2. Hepatic encephalopathy (spectrum of neuropsychiatric abnormalities in patients with liver failure)
  3. Hepatitis fulminant (life-threatening condition defined by significantly impaired liver function)
  4. Meningitis aseptic (a condition that causes the membranes covering your brain and spinal cord to become inflamed)
  5. Drug rash with eosinophilia and systemic symptoms (adverse drug reactions with rash)

50-59:

  1. Anaphylactic reaction (serious allergic reaction)
  2. Blood glucose increased
  3. Cardiac arrest
  4. Ketoacidosis (high concentrations of ketone bodies in blood)
  5. Seizure (abnormal excessive or synchronous neuronal activity in the brain)
  6. Shock (a life-threatening condition with symptoms like low blood pressure, weakness, shallow breathing, cold, clammy skin)

60+:

  1. Generalised erythema (redness of the skin all over the body)
  2. Skin exfoliation (removal of the oldest dead skin cells)
  3. General physical health deterioration (weak health status)

What are the existing conditions these people have? *

  1. Status Epilepticus (a life-threatening condition in which the brain is in a state of persistent seizure): 23 people, 43.40%
  2. Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures): 21 people, 39.62%
  3. Pneumonia Mycoplasmal (mycoplasma pneumonia (mp) is a contagious respiratory infection): 20 people, 37.74%
  4. Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 18 people, 33.96%
  5. Pain: 9 people, 16.98%
  6. Constipation: 9 people, 16.98%
  7. Oral Disorder (mouth disease): 7 people, 13.21%
  8. Lung Disorder (lung disease): 7 people, 13.21%
  9. Eye Infection: 7 people, 13.21%
  10. Diabetes: 7 people, 13.21%

* Approximation only. Some reports may have incomplete information.

Do you take Cefotaxime and Lamotrigine?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Cefotaxime and Lamotrigine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Cefotaxime:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Lamotrigine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Cefotaxime and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Lamotrigine and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on cefotaxime sodium and lamotrigine (the active ingredients of Cefotaxime and Lamotrigine, respectively), and Cefotaxime and Lamotrigine (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: